IMARA(IMRA) - 2025 Q1 - Quarterly Report

Financial Performance - For the three months ended March 31, 2025, total operating expenses were $31.7 million, an increase of 22% from $26.0 million in the same period in 2024[132]. - The net loss for Q1 2025 was $28.5 million, compared to a net loss of $22.7 million for Q1 2024, representing a 25% increase in losses[132]. - General and administrative expenses rose to $6.8 million for the three months ended March 31, 2025, compared to $6.0 million in the same period of 2024, an increase of 13.3%[135]. - Net cash used in operating activities was $24.1 million for the three months ended March 31, 2025, compared to $23.4 million for the same period in 2024, reflecting a 3.0% increase[148][149]. Research and Development - Research and development expenses for Q1 2025 were $24.9 million, up from $20.0 million in Q1 2024, reflecting a 25% increase[132]. - The company plans to advance the ELVN-001 program into Phase 1 safety/efficacy trials by mid-2025, focusing on a highly selective active site inhibitor for CML[111]. - The company intends to explore strategic alternatives for the ELVN-002 program and does not plan to pursue its development beyond 2025[110]. Cash and Funding - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $289.6 million, sufficient to fund operations for at least the next 12 months[115]. - The company raised $90.0 million in a private placement in March 2024, contributing to its funding strategy[115]. - The company has $200.0 million available for use under its shelf registration statement on Form S-3 as of March 31, 2025[138]. - The company expects to require substantial additional capital to fund operations and product development in the foreseeable future[140][141]. Revenue Generation - The company has not generated any revenue to date and does not expect to do so in the foreseeable future[122]. - The company has not generated any revenue from product sales to date and does not expect to do so until regulatory approval is obtained for its product candidates[140]. Debt and Financial Risk - As of March 31, 2025, the company had no debt outstanding, eliminating exposure to interest rate risk related to debt[160]. - A hypothetical 100 basis point increase or decrease in interest rates would not have a material impact on the company's financial results due to the short-term maturities of investments[159]. Foreign Currency Exposure - The company has limited contracts with vendors for research and development services denominated in foreign currencies, exposing it to potential foreign currency transaction gains or losses[161]. - The company does not currently engage in hedging activities to mitigate foreign currency exposure but may consider it in the future[161]. - The company believes that fluctuations in foreign exchange rates would not have a material impact on its financial condition or results of operations[161]. Accounting Policies - As of March 31, 2025, the company has not experienced material changes to its critical accounting policies and estimates since the last annual report[157]. - The company evaluates its estimates and assumptions periodically, acknowledging that actual results may differ from these estimates[157]. - Recent accounting pronouncements that may impact the company's financial condition are disclosed in the quarterly report[158]. - The company bases its estimates on historical experience, known trends, and various other factors deemed reasonable under the circumstances[157].